|Download document||Draft guideline on multiplicity issues in clinical trials|
|Status||draft: consultation open|
|Consultation start date||2017-04-01|
|Consultation end date||2017-06-30|
|Email address for email@example.com|
This guideline is intended to provide guidance on how to deal with multiple comparison and control of type I error in the planning and statistical analysis of clinical trials. From the points to consider document published in 2002, aspects related with multiplicity issues in safety, drug-response studies, secondary endpoints, subgroup analysis and estimation were added or updated, and statistical terms were clarified.